Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 8/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2596267 | 0.87 | HDAC2 (0.56) | HDAC2HDAC1HDAC3PTPN2PTPN1 | |
| SCHEMBL16426976 | 0.86 | PARP1 (0.48) | HDAC2HDAC1USP30STSPTPN2 | |
| SCHEMBL31079669 | 0.86 | PARP1 (0.48) | HDAC2HDAC1USP30STSPTPN2 | |
| SCHEMBL2593450 | 0.81 | HDAC1 (0.48) | HDAC2HDAC1HDAC3USP30PTPN2 | |
| SCHEMBL3334201 | 0.79 | HDAC1 (0.67) | HDAC2HDAC1HDAC3KMT2A | |
| SCHEMBL15711485 | 0.78 | ANO1 (0.50) | USP30STSPTPN2PTPN1PTPN6 | |
| SCHEMBL23149216 | 0.77 | NTRK1 (0.55) | HDAC2HDAC1USP30STSPTPN2 | |
| SCHEMBL29616628 | 0.77 | NTRK1 (0.55) | HDAC2HDAC1USP30STSPTPN2 | |
| SCHEMBL4635461 | 0.77 | ALDH1A1 (0.56) | HDAC2HDAC1USP30STSPTPN2 | |
| SCHEMBL30344192 | 0.77 | HDAC2 (0.46) | HDAC2HDAC1HDAC3PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946230-B2 | Aryl- and heteroaryl- nitrogen-heterocyclic compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2569299-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. | 2011-12-15 | — | — | US | disclosed |
| WO-2011143129-A1 | NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306590-A1 | ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS | HDAC10, PDE10A, PDE9A | HDAC2 43/4885HDAC1 11/4885HDAC3 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.